Bagegni N, Thomas S, Liu N et al. Serum thymidine kinase 1 activity as a pharmacodynamic marker of cyclin-dependent kinase 4/6 inhibition in patients with early-stage breast cancer receiving neoadjuvant palbociclib. Breast Cancer Res and Treat. 2017 Nov 21;19(1):123. doi: 10.1186/s13058-017-0913-7.
Bjohle J, Bergqvist J, Gronowitz JS et al. Serum thymidine kinase activity compared with CA 15-3 in locally advanced and metastatic breast cancer within a randomized trial. Breast Cancer Res and Treat 2013;139(3):751-8.
Nisman B, Kadouri L, Allweis T et al. Increased proliferative background in healthy women with BRCA1/2 haploinsufficiency is associated with high risk for breast cancer. Cancer Epidemiol Biomarkers Prev. 2013 Nov;22(11):2110-5.
Felix K, Hinz U, Dobiasch S, Hackert T el al. Preoperative Serum Thymidine Kinase Activity as Novel Monitoring, Prognostic, and Predictive Biomarker in Pancreatic Cancer. Pancreas. 2017 Nov 16. doi: 10.1097. [Epub ahead of print]
Nisman B, Appelbaum L, Yutkin V et. al. Serum Thymidine Kinase 1 Activity Following Nephrectomy for Renal Cell Carcinoma and Radiofrequency Ablation of Metastases to Lung and Liver. Anticancer Res. 2016 Apr;36(4):1791-7.
Nisman B, Yutkin V, Nechushtan H et al. Circulating Tumor M2 pyruvate kinase and thymidine kinase 1 are potential predictors for disease recurrence in renal cell carcinoma after nefrectomy. Urology 76 (2), 513. e1-e6, 2010.
Bacovsky J, Myslivecek M, Minarik J et al. Analysis of thymidine kinase serum levels by novel method DiviTum™ in multiple myeloma and monoclonal gammopathy of undetermined significance – comparison with imaging methods 99mTc-MIBI scintigraphy and 18F-FDG PET/CT. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015 Mar;159(1):135-8.
Nisman B, Allweis T, Kadouri L et al. Comparison of diagnostic and prognostic performance of two assays measuring thymidine kinase 1 activity in serum of breast cancer patients. Clin Chem Lab Med. 2013 ;51(2):439-47.
Perspective on Biomarkers covers important aspects of the use of biomarkers and has a primary focus on the use and applications of DiviTum™. The opportunities to provide improved tools for evaluating the efficacy of new oncology compounds and predict their efficacy are explored.
Pharmaceutical companies need to find not only good targets for therapies and good candidate drugs for these targets, they also need techniques to provide accurate and clinically meaningful data on the efficacy of these drugs. These techniques are what Biovica is developing and Perspective on biomarkers presents.